유육종증 치료제 시장 규모는 향후 몇 년 동안 강력한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 유육종증의 유병률 증가, 희귀 및 자가 면역 질환에 대한 인식 제고, 조기 발견을 가능하게 하는 진단 기술의 발전, 의료비 지출 증가, 전문 치료 및 생물학적 요법에 대한 환자의 접근성 개선에 기인할 수 있습니다. 예측 기간 동안 예상되는 주요 동향으로는 면역 치료 기술의 발전, 신약 개발에 인공 지능의 활용, 진단 영상 기술의 발전, 혁신적인 약물 전달 시스템의 개발, 디지털 건강 도구의 통합 등이 있습니다.
임상 시험의 수가 증가함에 따라 유육종증 치료제 시장의 성장이 촉진될 것으로 예상됩니다. 임상 시험은 의학적 치료 또는 중재의 안전성, 유효성 및 부작용을 평가하기 위해 인간을 대상으로 실시되는 연구입니다. 임상 시험의 증가는 철저한 안전성 및 유효성 테스트가 필요한 개인 맞춤형의 혁신적인 치료법에 대한 수요가 증가함에 따라 촉진되고 있습니다. 유육종증 치료제는 이러한 임상 시험에서 환자의 치료 결과를 개선하고 더 효과적인 치료법을 확인하기 위해 사용됩니다. 예를 들면, 런던에 본부를 두는 업계 단체인 영국 제약 공업 협회는 예를 들어, 2023년 11월 런던에 본사를 두고 있는 영국 제약 산업 협회(Association of the British Pharmaceutical Industry)는 영국에서 산업용 임상 시험의 연간 모집 인원이 2021-2022년의 3만 6,722명에서 2022-2023년에는 4만 2,088명으로 증가하는 것으로 보고했습니다.
유육종증 치료제 시장의 주요 기업들은 치료 저항성 사례를 해결하고 질병 관리의 성과를 높이기 위해 항 TNF-a 단일 클론 항체와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 이러한 생물학적 의약품은 종양 괴사 인자-알파(TNF-a)를 차단하여 유육종증 및 기타 자가 면역 질환과 같은 질환에서 염증과 조직 손상을 감소시킵니다. 2023년 11월, 미국에 본사를 둔 제약 회사인 Xentria Inc.는 유육종증 치료제인 XTMAB-16에 대해 유럽 의약청(EMA)으로부터 희귀 의약품 지정을 받았습니다. XTMAB-16은 유육종증의 특징인 육아종 형성에 관여하는 중요한 염증 분자인 TNFa를 표적으로 하는 인간-쥐의 키메라 단일 클론 항체입니다. 이 의약품은 염증 과정을 차단하고, 특히 폐에 영향을 미치는 폐 유육종증에서 육아종 형성을 늦출 수 있도록 설계되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 유육종증 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 유육종증 치료제 시장 : 성장률 분석
- 세계의 유육종증 치료제 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 유육종증 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 유육종증 치료제 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 유육종증 치료제 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 안구 유육종증
- 신경 유육종증
- 심장 유육종증
- 근골격 유육종증
- 피부 유육종증
- 신장 유육종증
- 간 유육종증
- 비장 및 골수 유육종증
- 폐 유육종증
- 세계의 유육종증 치료제 시장 작용기전별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 코르티코스테로이드
- 면역 억제제
- 항말라리아
- 종양 괴사 인자-알파(TNF-a) 억제제
- 세계의 유육종증 치료제 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 폐 병변
- 피부 병변
- 심장 병변
- 신경학적 관여
- 세계의 유육종증 치료제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 경구
- 정맥내
- 주사제
- 세계의 유육종증 치료제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 및 진료소
- 수술 센터
- 진단 센터
- 기타 최종 사용자
- 세계의 유육종증 치료제 시장 : 안구 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 전방 포도막염
- 후방 포도막염
- 포도막염
- 결막 유육종증
- 세계의 유육종증 치료제 시장 : 신경 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 뇌신경장애
- 수막 장애
- 척수 유육종증
- 말초신경장애
- 세계의 유육종증 치료제 시장 : 심장 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 부정맥
- 심장 차단
- 심근증
- 심부전
- 세계의 유육종증 치료제 시장 : 근골격 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 관절증
- 근병증
- 뼈 병변
- 유육종증 관절염
- 세계의 유육종증 치료제 시장 : 피부 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 루푸스 페르니오
- 결절성 홍반
- 구진성 병변
- 흉터 유육종증
- 세계의 유육종증 치료제 시장 : 신장 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 육아종성 간질성 신염
- 신장석증
- 고칼슘뇨증
- 요세관 간질성 신염
- 세계의 유육종증 치료제 시장 : 간 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 육아종성 간염
- 간 비대
- 담즙 정체
- 문맥압 항진증
- 세계의 유육종증 치료제 시장 : 비장 및 골수 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 비장종
- 비장 기능 항진증
- 골수 침윤
- 전혈구 감소증
- 세계의 유육종증 치료제 시장 : 폐 유육종증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 문맥 림프절 부종
- 간질성 폐질환
- 섬유성 유육종증
- 기관지 폐색
제7장 지역별, 국가별 분석
- 세계의 유육종증 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 유육종증 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 유육종증 치료제 시장 : 경쟁 구도
- 유육종증 치료제 시장 : 기업 프로파일
- AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis AG. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Viatris Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Boehringer Ingelheim International GmbH : 개요, 제품 및 서비스, 전략 및 재무 분석
- Aurobindo Pharma Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Mallinckrodt plc
- Kyorin Pharmaceutical Co. Ltd.
- Molecure SA
- aTyr Pharma Inc.
- Xentria Inc.
- Relief Therapeutics Holding AG
- Foresee Pharmaceuticals Co. Ltd.
- OrphAI Therapeutics Inc.
- Bellus Health Inc.
- AI Therapeutics Inc.
- Araim Pharmaceuticals Inc.
- Kinevant Sciences GmbH
- SarcoMed USA Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 유육종증 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
- 유육종증 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
- 유육종증 치료제 시장(2029년) : 성장 전략
제36장 부록
HBR
A sarcoidosis drug refers to any pharmacological substance used to manage the abnormal immune activity and granuloma development associated with sarcoidosis-a systemic inflammatory disease that primarily affects the lungs and lymph nodes. These medications work to alleviate symptoms and prevent damage to organs.
The primary types of sarcoidosis drugs are targeted for conditions such as ocular sarcoidosis, neurosarcoidosis, cardiac sarcoidosis, musculoskeletal sarcoidosis, cutaneous sarcoidosis, renal sarcoidosis, hepatic sarcoidosis, and sarcoidosis of the spleen, bone marrow, and lungs. Ocular sarcoidosis refers specifically to inflammation in the eyes caused by the disease, marked by the formation of granulomas in ocular tissues. This can lead to symptoms like redness, pain, and potential vision loss. Treatment approaches include corticosteroids, immunosuppressants, antimalarial drugs, and tumor necrosis factor-alpha (TNF-alpha) inhibitors. These medications are used to treat organ involvement in the lungs, skin, heart, and nervous system, and they can be administered orally, intravenously, or topically. Key end users include hospitals, clinics, surgical centers, diagnostic centers, and other healthcare institutions.
The sarcoidosis drug market research report is one of a series of new reports from The Business Research Company that provides sarcoidosis drug market statistics, including the sarcoidosis drug industry's global market size, regional shares, competitors with the sarcoidosis drug market share, detailed sarcoidosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis drug market. This sarcoidosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The sarcoidosis drug market size has grown strongly in recent years. It will grow from $7.43 billion in 2024 to $7.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be credited to increased investment in orphan drug development, expanded research and development efforts focused on granulomatous diseases, wider use of corticosteroids and immunosuppressants for symptom control, an expanding clinical pipeline of innovative sarcoidosis treatments, and a heightened emphasis on personalized and targeted therapeutic approaches.
The sarcoidosis drug market size is expected to see strong growth in the next few years. It will grow to $10.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to the rising prevalence of sarcoidosis, increased awareness of rare and autoimmune diseases, advancements in diagnostic techniques enabling earlier detection, higher healthcare spending, and improved patient access to specialty treatments and biologic therapies. Key trends expected during the forecast period include progress in immunotherapy technologies, the use of artificial intelligence in drug discovery, technological improvements in diagnostic imaging, the development of innovative drug delivery systems, and the incorporation of digital health tools.
The increasing number of clinical trials is expected to drive the growth of the sarcoidosis drug market. Clinical trials are research studies conducted on humans to assess the safety, effectiveness, and side effects of medical treatments or interventions. This rise in clinical trials is fueled by the growing demand for personalized and innovative treatments that require thorough safety and efficacy testing. Sarcoidosis drugs are used in these trials to evaluate their performance in improving patient outcomes and identifying more effective therapies. For example, in November 2023, the Association of the British Pharmaceutical Industry, a trade association based in London, reported a 15% increase in annual recruitment for industry clinical trials in the UK, with participant numbers rising from 36,722 in 2021-22 to 42,088 in 2022-23. As a result, the expanding number of clinical trials is contributing to the growth of the sarcoidosis drug market.
Major companies in the sarcoidosis drug market are focusing on the development of innovative therapies such as anti-TNFa monoclonal antibodies to address treatment-resistant cases and enhance disease management outcomes. These biologic drugs work by blocking tumor necrosis factor-alpha (TNFa), thereby reducing inflammation and tissue damage in conditions like sarcoidosis and other autoimmune diseases. In November 2023, Xentria Inc., a pharmaceutical company based in the US, received orphan drug designation from the European Medicines Agency (EMA) for XTMAB-16, a treatment for sarcoidosis. XTMAB-16 is a chimeric human-murine monoclonal antibody that targets TNFa, a critical inflammatory molecule involved in granuloma formation, which is characteristic of sarcoidosis. The drug is designed to interrupt the inflammatory process and potentially slow granuloma development, especially in pulmonary sarcoidosis, which impacts the lungs.
In June 2023, Xentria Inc. entered into a collaboration with Meitheal Pharmaceuticals Inc. to accelerate the development and commercialization of XTMAB-16. This partnership aims to deliver a targeted and effective treatment for pulmonary sarcoidosis, addressing a significant unmet medical need. Meitheal Pharmaceuticals Inc. is a US-based pharmaceutical manufacturer involved in the production of sarcoidosis drugs.
Major players in the sarcoidosis drug market are AbbVie Inc., Novartis AG., Viatris Inc., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt plc, Kyorin Pharmaceutical Co. Ltd., Molecure S.A., aTyr Pharma Inc., Xentria Inc., Relief Therapeutics Holding AG, Foresee Pharmaceuticals Co. Ltd., OrphAI Therapeutics Inc., Bellus Health Inc., AI Therapeutics Inc., Araim Pharmaceuticals Inc., Kinevant Sciences GmbH, SarcoMed USA Inc.
North America was the largest region in the sarcoidosis drug market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sarcoidosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the sarcoidosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The sarcoidosis drug market consists of sales of hydroxychloroquine, leflunomide, and cyclophosphamide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sarcoidosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on sarcoidosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for sarcoidosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarcoidosis drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Ocular Sarcoidosis; Neurosarcoidosis; Cardiac Sarcoidosis; Musculoskeletal Sarcoidosis; Cutaneous Sarcoidosis; Renal Sarcoidosis; Hepatic Sarcoidosis; Sarcoidosis Of The Spleen and Bone Marrow; Pulmonary Sarcoidosis
- 2) By Mechanism of Action: Corticosteroid; Immunosuppressants; Antimalarial; Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
- 3) By Indication: Lung Involvement; Skin Involvement; Cardiac Involvement; Neurological Involvement
- 4) By Route of Administration: Oral; Intravenous; Topical
- 5) By End User: Hospitals And Clinics; Surgical Centers; Diagnostic Centers; Other End Users
Subsegments
- 1) By Ocular Sarcoidosis: Anterior uveitis; Posterior uveitis; Panuveitis; Conjunctival sarcoidosis
- 2) By Neurosarcoidosis: Cranial neuropathy; Meningeal involvement; Spinal cord sarcoidosis; Peripheral neuropathy
- 3) By Cardiac Sarcoidosis: Arrhythmias; Heart block; Cardiomyopathy; Heart failure
- 4) By Musculoskeletal Sarcoidosis: Arthropathy; Myopathy; Bone lesions; Sarcoid arthritis
- 5) By Cutaneous Sarcoidosis: Lupus pernio; Erythema nodosum; Maculopapular lesions; Scar sarcoidosis
- 6) By Renal Sarcoidosis: Granulomatous interstitial nephritis; Nephrocalcinosis; Hypercalciuria; Tubulointerstitial nephritis
- 7) By Hepatic Sarcoidosis: Granulomatous hepatitis; Hepatomegaly; Cholestasis; Portal hypertension
- 8) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly; Hypersplenism; Bone marrow infiltration; Pancytopenia
9) By Hilar lymphadenopathy; Interstitial lung disease; Fibrotic sarcoidosis; Bronchial obstruction
- Companies Mentioned: AbbVie Inc.; Novartis AG.; Viatris Inc.; Boehringer Ingelheim International GmbH; Aurobindo Pharma Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Sarcoidosis Drug Market Characteristics
3. Sarcoidosis Drug Market Trends And Strategies
4. Sarcoidosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Sarcoidosis Drug Growth Analysis And Strategic Analysis Framework
- 5.1. Global Sarcoidosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Sarcoidosis Drug Market Growth Rate Analysis
- 5.4. Global Sarcoidosis Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Sarcoidosis Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Sarcoidosis Drug Total Addressable Market (TAM)
6. Sarcoidosis Drug Market Segmentation
- 6.1. Global Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ocular Sarcoidosis
- Neurosarcoidosis
- Cardiac Sarcoidosis
- Musculoskeletal Sarcoidosis
- Cutaneous Sarcoidosis
- Renal Sarcoidosis
- Hepatic Sarcoidosis
- Sarcoidosis of the Spleen and Bone Marrow
- Pulmonary Sarcoidosis
- 6.2. Global Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Corticosteroid
- Immunosuppressants
- Antimalarial
- Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
- 6.3. Global Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Lung Involvement
- Skin Involvement
- Cardiac Involvement
- Neurological Involvement
- 6.4. Global Sarcoidosis Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravenous
- Topical
- 6.5. Global Sarcoidosis Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals And Clinics
- Surgical Centers
- Diagnostic Centers
- Other End Users
- 6.6. Global Sarcoidosis Drug Market, Sub-Segmentation Of Ocular Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anterior uveitis
- Posterior uveitis
- Panuveitis
- Conjunctival sarcoidosis
- 6.7. Global Sarcoidosis Drug Market, Sub-Segmentation Of Neurosarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cranial neuropathy
- Meningeal involvement
- Spinal cord sarcoidosis
- Peripheral neuropathy
- 6.8. Global Sarcoidosis Drug Market, Sub-Segmentation Of Cardiac Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Arrhythmias
- Heart block
- Cardiomyopathy
- Heart failure
- 6.9. Global Sarcoidosis Drug Market, Sub-Segmentation Of Musculoskeletal Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Arthropathy
- Myopathy
- Bone lesions
- Sarcoid arthritis
- 6.10. Global Sarcoidosis Drug Market, Sub-Segmentation Of Cutaneous Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Lupus pernio
- Erythema nodosum
- Maculopapular lesions
- Scar sarcoidosis
- 6.11. Global Sarcoidosis Drug Market, Sub-Segmentation Of Renal Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Granulomatous interstitial nephritis
- Nephrocalcinosis
- Hypercalciuria
- Tubulointerstitial nephritis
- 6.12. Global Sarcoidosis Drug Market, Sub-Segmentation Of Hepatic Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Granulomatous hepatitis
- Hepatomegaly
- Cholestasis
- Portal hypertension
- 6.13. Global Sarcoidosis Drug Market, Sub-Segmentation Of Sarcoidosis Of The Spleen And Bone Marrow, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Splenomegaly
- Hypersplenism
- Bone marrow infiltration
- Pancytopenia
- 6.14. Global Sarcoidosis Drug Market, Sub-Segmentation Of Pulmonary Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hilar lymphadenopathy
- Interstitial lung disease
- Fibrotic sarcoidosis
- Bronchial obstruction
7. Sarcoidosis Drug Market Regional And Country Analysis
- 7.1. Global Sarcoidosis Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Sarcoidosis Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Sarcoidosis Drug Market
- 8.1. Asia-Pacific Sarcoidosis Drug Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Sarcoidosis Drug Market
- 9.1. China Sarcoidosis Drug Market Overview
- 9.2. China Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Sarcoidosis Drug Market
- 10.1. India Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Sarcoidosis Drug Market
- 11.1. Japan Sarcoidosis Drug Market Overview
- 11.2. Japan Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Sarcoidosis Drug Market
- 12.1. Australia Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Sarcoidosis Drug Market
- 13.1. Indonesia Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Sarcoidosis Drug Market
- 14.1. South Korea Sarcoidosis Drug Market Overview
- 14.2. South Korea Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Sarcoidosis Drug Market
- 15.1. Western Europe Sarcoidosis Drug Market Overview
- 15.2. Western Europe Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Sarcoidosis Drug Market
- 16.1. UK Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Sarcoidosis Drug Market
- 17.1. Germany Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Sarcoidosis Drug Market
- 18.1. France Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Sarcoidosis Drug Market
- 19.1. Italy Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Sarcoidosis Drug Market
- 20.1. Spain Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Sarcoidosis Drug Market
- 21.1. Eastern Europe Sarcoidosis Drug Market Overview
- 21.2. Eastern Europe Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Sarcoidosis Drug Market
- 22.1. Russia Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Sarcoidosis Drug Market
- 23.1. North America Sarcoidosis Drug Market Overview
- 23.2. North America Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Sarcoidosis Drug Market
- 24.1. USA Sarcoidosis Drug Market Overview
- 24.2. USA Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Sarcoidosis Drug Market
- 25.1. Canada Sarcoidosis Drug Market Overview
- 25.2. Canada Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Sarcoidosis Drug Market
- 26.1. South America Sarcoidosis Drug Market Overview
- 26.2. South America Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Sarcoidosis Drug Market
- 27.1. Brazil Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Sarcoidosis Drug Market
- 28.1. Middle East Sarcoidosis Drug Market Overview
- 28.2. Middle East Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Sarcoidosis Drug Market
- 29.1. Africa Sarcoidosis Drug Market Overview
- 29.2. Africa Sarcoidosis Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Sarcoidosis Drug Market, Segmentation By Mechanism of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Sarcoidosis Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Sarcoidosis Drug Market Competitive Landscape And Company Profiles
- 30.1. Sarcoidosis Drug Market Competitive Landscape
- 30.2. Sarcoidosis Drug Market Company Profiles
- 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis
31. Sarcoidosis Drug Market Other Major And Innovative Companies
- 31.1. Hikma Pharmaceuticals PLC
- 31.2. Lupin Limited
- 31.3. Mallinckrodt plc
- 31.4. Kyorin Pharmaceutical Co. Ltd.
- 31.5. Molecure S.A.
- 31.6. aTyr Pharma Inc.
- 31.7. Xentria Inc.
- 31.8. Relief Therapeutics Holding AG
- 31.9. Foresee Pharmaceuticals Co. Ltd.
- 31.10. OrphAI Therapeutics Inc.
- 31.11. Bellus Health Inc.
- 31.12. AI Therapeutics Inc.
- 31.13. Araim Pharmaceuticals Inc.
- 31.14. Kinevant Sciences GmbH
- 31.15. SarcoMed USA Inc.
32. Global Sarcoidosis Drug Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Sarcoidosis Drug Market
34. Recent Developments In The Sarcoidosis Drug Market
35. Sarcoidosis Drug Market High Potential Countries, Segments and Strategies
- 35.1 Sarcoidosis Drug Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Sarcoidosis Drug Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Sarcoidosis Drug Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
